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Sudden  sensorineural  hearing  loss  (SSNHL)  is  a common  and  alarming  symptom  that  often  prompts  an
urgent visit  to  an  ENT  specialist.  Treatment  of  SSNHL  remains  one  of  the  most  problematic  issues  for  con-
temporary  otorhinolaryngology:  although  many  meta-analyses  and  national  guidelines  have  been  issued,
management  is not  standardized  in  terms  of  medical  treatment,  and duration  and  route  of  administra-
tion.  We  present  several  methodological  suggestions  for the  study  of  treatments  for SSNHL.  These  were
developed  from  the  existing  level  of evidence  of  the  main  treatments  used  in  SSNHL  by  experts  who
convened  at  the  IFOS  2017  ENT  World  Congress  in  Paris,  France.  All  panelists  agreed  that  one  of the main
limitations  present  in studies  on SSNHL  is  related  to the  wide  heterogeneity,  which  characterizes  both  the
initial  hearing  deﬁcit  and the  amount  of hearing  recovery.  Although  evidence  of the  efﬁcacy  of systemic
steroids  cannot  be considered  as strong  enough  to recommend  their  use,  it is  still the most  widespread
primary  therapy  and  can  be  considered  as  the current  standard  of care.  Therefore,  systemic  steroids  stand
as an  adequate  control  for any  innovative  treatment.  To  reduce  the  number  of subjects  we  suggest  that
the  inclusion  criteria  should  be  restricted  to moderate  to  profound  levels  of  hearing  loss.  The efﬁcacy  of
trans-tympanic  steroids  as  a salvage  therapy  was  suggested  in  several  reports  on  small  populations  and
needs to be  conﬁrmed  with  larger  randomized  controlled  trials.
©  2018  Elsevier  Masson  SAS.  All  rights  reserved.
1. Introduction
Although sudden sensorineural hearing loss (SSNHL) has a rel-
atively low incidence of 5 and 30 cases per 100,000 per year [1], it
is considered one of the most common emergencies in ENT prac-
tice. SSNHL is usually deﬁned as a unilateral hearing loss of at least
30 dB HL in three consecutive frequencies in the standard pure-
tone audiogram [1,2] and can present at varying levels of severity
from mild to total. SSNHL is considered idiopathic in the absence
of established etiology, although several pathophysiological
∗ Corresponding author.
E-mail address: marx.m@chu-toulouse.fr (M.  Marx).
hypotheses have been proposed. The most common theories
include viral infection [3,4], rupture of the cochlear membrane
[5,6] and vascular accident [7–9]. The evolution of the condition
is marked by a high rate of spontaneous recovery; estimated at 32%
to 65% in case histories and placebo-controlled studies [10–12]. The
audiogram characteristics have been shown to inﬂuence the evo-
lution [11–14] with low and mid-frequency hearing losses given
a better prognosis that ﬂat and severe losses. There is general
agreement that the management of SSNHL should start with diag-
nostic MRI  scanning of the cerebello-pontine angle to discard a
vestibular schwannoma [1,2,15,16] and search for a demyelinat-
ing process or a labyrinthine haemorrhage [17]. The treatment of
SSNHL appears more controversial and the necessity of medication
has even been questioned by several authors [18,19]. Different ther-
apeutic approaches are based on the supposed pathophysiological
https://doi.org/10.1016/j.anorl.2017.12.011
1879-7296/© 2018 Elsevier Masson SAS. All rights reserved.
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mechanisms responsible for inner ear dysfunction: For example
steroids to reduce the supposed inﬂammatory response to hyper-
baric oxygenation to reverse the lack of oxygen in the inner ear. The
heterogeneity of hearing deﬁcits and their evolution, the diversity
of possible causes and corresponding treatments are all factors that
challenge evidence-based practice.
Several systematic reviews of the literature have been con-
ducted on the effectiveness of steroids as a treatment for SSNHL
in randomized controlled trials (RCT). By far most of these under-
lined the heterogeneity of inclusion criteria or outcome measures.
Indeed, the inclusion of subjects with highly variable levels of hear-
ing loss, accompanying symptoms (vertigo and tinnitus) or delays
after onset of hearing loss can lead to a signiﬁcant risk of selec-
tion bias and unmatched groups. Likewise, the wide variety of
criteria used to describe the evolution of hearing function, from
different deﬁnitions of pure-tone average threshold to multiple
categorical classiﬁcations, reduces the relevance of comparisons
made between studies. As a result, steroids are one of the most used
options among the therapeutic armamentarium without any strong
recommendation to refer to. Oral steroids are usually proposed as
a ﬁrst-line treatment based on an evaluation of the ratio risk ver-
sus beneﬁt. The potential consequences of unilateral SSNHL may  be
severe in terms of quality of life, because of the impact on speech
recognition in noise, on sound localization and because of the inca-
pacitating tinnitus sometimes associated [19–21]. In contrast, the
side effects expected from an acute therapy with oral steroids are
mild [22,23]. Trans-tympanic steroids can also be proposed as a sin-
gle primary therapy [22], but have more frequently been assessed
in combination with systemic steroids [24] or as a salvage therapy
[25].
This present consensus conference was held in Paris during
the International Federation of Oto-rhino-laryngological Societies
(IFOS) 2017 congress, with two purposes: The ﬁrst objective was
to provide an updated and documented overview of the level
of evidence supporting the treatment of SSNHL with systemic
and trans-tympanic steroids. The second goal of this international
consensus conference was to identify methodological guidelines,
which should be considered when designing studies on treatments
for SSNHL.
Members of the discussion panel were S. Chandrasekhar (USA),
J. Ito (Japan), S. Plontke (Germany) and S. O’Leary (Australia), each
one being an international leading expert in the ﬁeld on SSNHL.
The discussion was moderated by M.  Marx (France) and O. Sterkers
(France).
1.1. Level of evidence for the use of steroids
1.1.1. Systemic steroids
Systemic steroids as a treatment for SSNHL have been exten-
sively studied since the hallmark work by Wilson et al. in 1980
[26]. This paper is often cited (> 900 citations) to support the effec-
tiveness of systemic steroids and warrants some further discussion:
based on a signiﬁcant difference between the proportion of patients
who improved in the group who received steroids (20/33 subjects
i.e. 61%) and the proportion in the placebo-controlled group (11/34,
i.e. 32%), the authors concluded that steroids improved hearing
better than placebo, and more speciﬁcally in a “steroid-effective”
zone corresponding to moderate hearing loss. In fact, patients were
included in two different centers with different steroid treatments
(dexamethasone and methylprednisolone) at varying doses. The
distribution of age; prevalence of accompanying symptoms such
as vertigo; and audiogram proﬁles differed between treatment
group and control group so that the randomization procedure was
inadequate if at all present. Furthermore, there was a signiﬁcant
difference in the rate of recovery between the two centers both for
oral steroids (73% versus 36%) and for placebo (50% versus 31%) so
that the data should not have been pooled.
However, this article was  selected for review in the Cochrane
work on this topic, ﬁrst published in 2006 and most recently
updated in 2013 [27]. In this review, only 3 publications were
included despite more than 200 studies being described as RCTs.
In the same way, two [28,29] to four papers [26,28–30] were
eventually selected over hundreds of studies in several reviews or
meta-analyses [31–33] because of the global rarity of genuine RCTs.
As for the Cochrane review and the clinical guidelines of the Ameri-
can Academy of Otolaryngology – Head & Neck Surgery (AAO-HNS)
these papers [31–33] concluded that systemic steroids were not
proven as either effective or ineffective. No recommendation can
therefore be made for or against their usage, but because of the
potentially severe consequences of SSNHL, the AAO-HNS guideline
suggested using them as an option. The most common dose used for
the prescription of oral prednisolone is 60 mg  per day (i.e. approx-
imately 1 mg/kg) but higher doses are for instance recommended
in Germany (at least 250 mg  per day for the ﬁrst three days [34]).
A recent RCT comparing high-doses (500 mg  per day for three days
followed by 60 mg  per days for 11 days) to the common regimen
(60 mg per day for 14 days) showed no signiﬁcant beneﬁt of using
higher doses [35]. Nevertheless, it should be noted that the number
of subjects needed to treat was not reached (67 subjects included
versus 106 calculated).
1.1.2. Trans-tympanic steroids
The main theoretical advantage of trans-tympanic steroids
relies on the bypass of the blood-labyrinthine barrier to reach
higher concentrations in the inner ear [36,37]. Further, this mode of
administration avoids the undesirable effects of systemic steroids.
The global effectiveness of trans-tympanic steroids in the treat-
ment of SSNHL is hard to determine because they may be used as
a primary therapy alone [22,38–41] or in combination with sys-
temic steroids [24,42,43], or as a salvage therapy after failure of
systemic steroids [25,44–46]. Several recent meta-analyses [47,48]
showed no signiﬁcant difference in terms of pure-tone average
(PTA) improvement and recovery rate between systemic and trans-
tympanic steroids, when used as a primary therapy. However, the
meta-analysis by Qiang et al. [49] found a better recovery rate in a
total of 225 pooled subjects who received a ﬁrst-line treatment by
trans-tympanic steroids compared to 226 pooled control subjects
(systemic steroids), especially in subjects with mild to moderate
hearing loss. An ongoing Cochrane review led and presented by
S. Plontke emphasizes that the majority of such RCTs include small
samples and offer limited possibilities to assess the risk of bias.
Most studies on the use of trans-tympanic steroids as a sal-
vage therapy showed at least a tendency to obtain better results
than control for PTA improvement and/or the rate of recovery
[25,44–46]. As a result, a recent meta-analysis performed on ﬁve
studies [25,44–46,50] found a mean PTA improvement of 11.54 dB
for trans-tympanic steroids versus 2.68 dB for placebo or no treat-
ment controls [51]. The limited sample size of generally < 30 should
also be taken into account for the interpretation of such results.
The main RCTs using systemic and/or trans-tympanic steroids as a
primary therapy are summarized in Table 1.
1.2. Methodological implications
RCTs are unanimously acknowledged as the gold standard in
evaluating the effectiveness of a treatment, but not all RCTs are
equal in value, which is particularly true in the ﬁeld of SSNHL. Sig-
niﬁcant limitations, from the conception of the study design up to
the reporting of the methods and outcomes, were cause for rejec-
tion of these studies in the recently updated Cochrane review [27].
The general low quality of trials on SSNHL is regularly underlined in
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Table  1
Study characteristics of systemic steroids and/or trans-tympanic steroids (TTS) as a primary therapy for SSNHL.
Authors Number of
subjects (n)
Comparison Outcome
measures
Outcomes
Systemic steroids
Wilson et al., 1980 n = 67 Steroids (n = 33, two different
steroid treatments) vs. placebo
(n = 34)
One “control” group of 52 (or
53?) subjects added; without
any treatment
Hearing recovery: complete:
within 10 dB of initial PTA/SRT;
partial: > 50% of initial PTA/SRT; no
recovery: < 50% of initial PTA/SRT
If hearing loss > 90 dB, no effect of
steroids
Deﬁnition of a “steroid-effective
zone”, with hearing better than
90 dB
Rate of recovery in the
placebo-controlled study for
hearing losses < 90 dB: 91% with
steroids vs. 40% with placebo in
one center, 57% vs. 36% in the other
Nosrati  and Hultcrantz, 2012 n = 93 Prednisone (n = 47) vs. placebo
(n = 46)
PTA and rate of PTA improvement
(> 10 dB)
Rate of complete recovery (within
10 dB of initial PTA)
No signiﬁcant difference between
prednisone and placebo at day 90:
mean PTA improvement of 39 dB
(± 20.1) with prednisone, 35.1 dB
(± 38.3) with placebo; 18/47
complete recovery with
prednisone, 18/46 complete
recovery with placebo
Cinamon et al., 2001 n = 41 Carbogen inhalation (n = 11),
room air (n = 9), prednisone
(n  = 10), placebo (n = 11)
Rate of PTA improvement (> 15 dB) Overall improvement = 73.1%
(30/41)
No difference between 4 groups
Eftekharian et al., 2015 n = 67 Pulse steroid therapy (n = 29)
with 500 mg/day for 3 days
then 60 mg/day vs. standard
steroid treatment (n = 31) with
60 mg/day
Pure-tone improvement per
frequency (0.5, 1, 2, 3, 4 kHz)
Word recognition score
improvement
Complete, partial or absence of
recovery, as deﬁned by the
AAO-HNSa
No difference between groups for
pure-tone, word recognition
scores, or rate of recovery
Group pulse: 7/29 complete, 10/29
partial, 12/29 no recovery
Group standard: 6/31 complete,
11/31 partial, 14/31 no recovery
Trans-tympanic steroids
Lim et al., 2012 n = 60 Oral steroids (20), TTS (20),
oral and TTS combined (20)
PTA and SRT improvements
Complete, partial or absence of
recovery, as deﬁned by the
AAO-HNSa
No signiﬁcant difference between
groups. Trend for better results
combined therapy (mean
improvement of 22 dB vs. 12.1 dB
and 12.8 dB for oral or TTS alone)
Rauch  et al., 2011 n = 250 Oral steroids (n = 129) vs. TTS
(n = 129)
PTA and rate of PTA improvement
(> 10 dB)
Rate of complete recovery
(PTA < 30 dB)
Word recognition score
No inferiority of TTS compared to
oral steroids: 28.7 dB vs. 30.7 dB
PTA improvement; 24% vs. 20% of
complete recovery
Swachia et al., 2016 n = 42 Oral steroids (n = 21) vs. TTS
(n  = 21)
PTA improvement
Furuhashi criteriab
No signiﬁcant difference between
groups: improvement of
18.24 ± 8.72 dB with oral
prednisone and 14.68 ± 12.88 dB
with TTS
Gundogan et al., 2013 n = 73 Oral steroids (n = 36) vs. oral
and TTS combined (n = 37)
PTA improvement
Word recognition score
Siegel’s criteriac
Signiﬁcantly better results with
combined therapy on: PTA: 44
dB ± 21.5 vs. 25.7 dB ± 19.8
improvement; word recognition
score and rate of recovery
Filippo et al., 2013 n = 50 TTS (n = 25) vs. placebo (n = 25).
If no improvement at day 7,
supplementary oral
prednisolone given for 8 days
PTA improvement
Furuashi criteriab
At day 7, signiﬁcantly better results
with TTS over placebo on: PTA
improvement; rate of recovery
(19/25 complete recovery with TTS
vs. 5/25 with placebo); 1 month
after, no signiﬁcant difference
between groups
Hong  et al., 2009 n = 63 Oral steroids (n = 31) vs. TTS
(n  = 32)
PTA and pure-tone thresholds
improvement
Siegel’s criteriac
Signiﬁcant difference for pure-tone
improvement in high frequencies:
better with oral steroids
No signiﬁcant difference for the
rate of recovery
Dispenza et al., 2011 n = 46 Oral steroids (n = 21) vs. TTS
(n  = 25)
PTA and rate of PTA improvement
(> 10 dB)
No signiﬁcant difference between
groups: 20/25 with TTS and 17/21
with oral steroids; numbers for
PTA improvements not reported
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Table  1
(Continued)
Authors Number of
subjects (n)
Comparison Outcome
measures
Outcomes
Battaglia et al., 2008 n = 51 TTS + oral placebo taper (n = 17)
vs. high-dose prednisone taper
(HDPT) and trans-tympanic
placebo injections (n = 18) vs.
combined TTS and HDPT
(n = 16)
PTA and rate of PTA improvement
(> 15 dB)
Word recognition score and rate of
improvement > 25% points
Greater improvement for PTA and
word recognition with combined
therapy
Better rate of complete recovery
for combined therapy compared to
treatment by HDPT
SSNHL: sudden sensorineural hearing loss; PTA: pure-tone average; SRT: speech recognition threshold.
a AAO-HNS criteria. Complete recovery with return to within 10 dB HL of the unaffected ear and recovery to word recognition score to within 5% to 10% of the unaffected
ear.  Partial recovery deﬁned in 2 ways (clinically meaningful/not meaningful recovery based on whether or not the degree of initial hearing loss after SSNHL rendered the
ear  nonserviceable). No recovery: anything less than 10 dB HL.
b Furuashi criteria. Complete recovery: PTA ≤ 25 dB HL or identical to the contralateral non-affected ear. Marked recovery: PTA improvement > 30 dB HL. Slight recovery:
PTA  improvement between 10 and 30 dB HL. No recovery: anything less than 10 dB HL.
c Siegel’s criteria. Complete recovery: PTA ≤ 25 dB HL or identical to the unaffected ear. Partial improvement if improvement > 15 dB HL and ﬁnal PTA between 25 and 45 dB
HL.  Slight improvement if improvement > 15 dB HL and ﬁnal PTA poorer 45 dB HL. No recovery if improvement ≤ 15 dB HL and ﬁnal PTA poorer than 75 dB HL.
the conclusion of other literature reviews or meta-analyses [31,33].
It must be recognized that the relative rarity of SSNHL, combined
with the heterogeneous level of hearing deﬁcits and the high rate of
spontaneous recovery, usually complicates the conception of stud-
ies and the analyses of the outcomes. But several suggestions were
made during the international consensus conference to improve
the global quality of RCTs in that ﬁeld.
1.2.1. Inclusion criteria
Although it has an impact on the ease of recruitment, the restric-
tion of inclusion criteria is a good solution to reduce the initial
heterogeneity, and the level of hearing loss is probably the most
variable characteristic in subjects with SSNHL. Several valuable
studies thus selected only patients with moderate hearing loss [52]
or with at least moderate hearing loss [22,25,35] to study the effect
of steroids in a relatively homogeneous populations. It might be all
the more relevant to focus on these patients as the probability of
spontaneous recovery (and its inﬂuence on outcomes) is reduced
in case of severe to profound hearing loss [10,11,53].
1.2.2. Outcome measures
The question of the outcome measures, which should be cho-
sen is prominently controversial. This can be illustrated by the
multiplicity of categorical criteria existing in the literature. The
landmark study by Wilson et al. [26] deﬁned recovery as complete
if the follow-up PTA (dB HL) or speech recognition threshold (SRT)
improved to within 10 dB of pre-sudden hearing loss hearing lev-
els. Complete recovery was differently deﬁned using Furuashi or
Siegel’s criteria as a ﬁnal PTA better than 25 dB HL [43,52,54,55], or
by the ministry of health, Labor and Welfare in Japan as ﬁnal PTA
better than 20 dB HL [56]. If the deﬁnition of complete recovery is
so problematic, it is not hard to imagine the variety of deﬁnitions
for “marked” or “slight” recovery. Likewise, the restoration of useful
hearing is a notion, which may  generate multiple interpretations.
In certain patients, it can refer to PTA allowing speech recognition
with a hearing aid. In others, the restoration of hearing thresholds
compatible with the perception of some environmental sounds.
It is obvious that “ideal” hearing measurements should include
pre- and post-treatment pure-tone thresholds and word recogni-
tion scores but the reporting of the evolution of these parameters
remains problematic. To compensate for the lack of standardization
for reporting combinations of hearing performance Gurgel et al.
[57] proposed a classiﬁcation system basing on a scattergram; they
plotted pure-tone thresholds against recognition scores for words.
However, this is still mainly used only for the English language.
Furthermore, there is unfortunately no validated tool to assess
the equivalence of speech recognition tests across the different
languages and pure-tone audiogram remains the only true inter-
national common standard.
Therefore, the panelists suggested using the change in pure-tone
thresholds as the primary outcome measure for studies on treat-
ments for SSNHL. It was  added that any PTA change exceeding 10 dB
HL could be considered as signiﬁcant if the audiometry was  per-
formed under adequately controlled conditions [58]. Besides the
absolute evolution of pure-tone thresholds a 10 dB change in PTA
could thus serve as a categorical criterion to determine the pres-
ence or absence of hearing improvement. Likewise, the use of ﬁnal
pure-tone threshold allows the deﬁnition of complete recovery as
a secondary outcome measure. The evolution of speech recogni-
tion scores after treatment remains highly informative, as well as
the proportion of subjects improving in each treatment group for
PTA and word recognition. The duration between the onset of the
hearing loss and the ﬁnal PTA measurement is also variable in the
literature, from 30 days [52] to 3 months [30], although longer
intervals allow including delayed recoveries.
1.2.3. Calculation of the sample size
The calculation of the sample size is an element regularly lack-
ing in studies on SSNHL although it should appear as stated in
the general guidelines for the reporting of randomized controlled
trial published by the Consolidated Standards of Reporting Trials
(CONSORT) group [59]. It is not uncommon to calculate numbers of
subjects needed to treat greater than 150–200 to show an advan-
tage of a treatment over natural evolution with the signiﬁcant
rate of spontaneous recovery [60]. However, such sample sizes are
built upon the assumption that all patients can improve, while
the inter-individual variability for hearing recovery is an intrin-
sic characteristic of SSNHL. Actually, both spontaneous evolution
and uneven distribution of recovery should be taken into account
to model the sample size. During his presentation, S. O’Leary
demonstrated that this number could decrease signiﬁcantly if only
subjects with moderate and more severe levels of hearing loss were
included. He also emphasized the need to apply non-parametric
statistics to the analyses of the outcomes because of the non-normal
distribution of hearing recovery.
1.2.4. The control group
The nature of the control group is also a matter of debate and
inﬂuences the choice of hypothesis. The question of effectiveness
of a new treatment for SSNHL theoretically requires a placebo con-
trol. Numerous RCTs were for instance excluded from the Cochrane
review because the true effect of steroids could not be determined
in the absence of such a group [22,37,38,41,61–67]. However, some
of these studies addressed a more relevant question from a clinical
point of view, which is the superiority of a new treatment over the
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standard of care. Systemic steroids can be considered as the current
clinical practice and are for sure the most widely used treatment, as
demonstrated in several surveys [68,69] with rates of prescription
by otolaryngologists as high as 100% [69]. These clinical consid-
erations question the ethical value of placebo in the assessment
of treatments for SSNHL. All panelists agreed that a new treat-
ment should provide better hearing results than steroids to deserve
further attention from the medical community but also from the
regulatory authorities.
Insulin-like growth factor-1 (IGF1) in topical application to treat
SSNHL is a good example of an innovative therapy: IGF-1 plays
a role in the protection of cochlear hair cells [69,70] which may
be damaged to various degrees in cases of SSNHL. Initial animal
experiments showed the safety of IGF-1 and suggested its efﬁ-
cacy by protecting hair cells from noise exposure, ischemic injury
[69,71,72] and ototoxic drugs [70]. Pilot clinical trials in a limited
number of subjects with refractory SSNHL followed these results
to demonstrate safety and efﬁcacy of trans-tympanic topical IGF-1
delivered using gelatin hydrogels [73,74]. A larger multicenter RCT
was ﬁnally performed to compare topical IGF-1 to the standard
trans- tympanic dexamethasone treatment as a salvage therapy
[75]. In this RCT the primary outcome measure was  the rate of
improvement (change in PTA > 10 dB). The sample size (n = 120) was
calculated basing on the expected proportions of subjects improv-
ing after each treatment determined by the previous clinical trials
for IGF-1 and the main recent ﬁndings in the literature for dex-
amethasone. Randomization was stratiﬁed by the mean hearing
thresholds to distribute equally the number of profound hearing
losses. The primary objective of the trial was not achieved because
the proportion of subjects improved did not differ signiﬁcantly
between the two groups with a rate of 66.7% in IGF-1 group and
53.6% in dexamethasone group, but the change in PTA was more
favorable in IGF-1.
2. Conclusion
SSNHL is a difﬁcult condition to study because of the wide het-
erogeneity, which characterizes both the initial hearing deﬁcits and
the amount of hearing recovery. Although the evidence support-
ing their efﬁcacy is still debated, systemic steroids are the most
widespread primary therapy and stand as an adequate control for
any innovative treatment for SSNHL. Likewise, the true effect of
trans-tympanic steroids used as a salvage therapy is debatable but
several RCTs showed signiﬁcant hearing improvements in compar-
ison to control groups.
The statistical power of studies may  be increased by restrict-
ing inclusion to moderate and more severe levels of hearing loss
and/or by the use of a stratiﬁed randomization. When modelled,
this restriction has also an inﬂuence on the calculation of the sam-
ple size, requiring a lower number of study subjects. Changes in
pure-tone thresholds are currently the only common, international
outcome measure and should therefore be employed in primary
end-points.
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